Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTEY1L)

Drug Name

BMS-986315 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting NKG2-A/B-activating NK receptor (NKG2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN8765	DMCFPBE	Rheumatoid arthritis	FA20	Phase 2	[2]
Monalizumab	DMG7XHE	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[3]
IM1240	DMTV0DK	Aggressive cancer	2A00-2F9Z	Preclinical	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NKG2-A/B-activating NK receptor (NKG2A)	TTC4IMS	NKG2A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Purple